The Human Insulin Market exhibited robust performance, boasting a value of USD 19.21 billion in 2023. Forecasts paint an optimistic picture, projecting a climb to USD 24.71 billion by 2031, with a steady growth rate of 3.2% during the forecast period spanning from 2024 to 2031. This upward trajectory signifies the increasing significance of human insulin in the healthcare landscape, driven by factors such as the rising prevalence of diabetes globally, advancements in insulin delivery systems, and growing awareness about the importance of diabetes management. As the demand for effective diabetes treatments continues to soar, the human insulin market is poised for sustained expansion in the coming years.